The FDA announced on Feb. 28, 2018, that Osmotica Pharmaceutical Corp voluntarily recalled Methylphenidate Hydrochloride Extended-release Tablets due to subpotency risks. The agency stated the recall was initiated by the firm.
How to tell if you have it
- Brand: Osmotica
- Product: Methylphenidate Hydrochloride Extended-release Tablets, USP, 36 mg, 100-count bottle
- NDC: 13811-708-10
- Lots: 170231B, 170232A, 170233A, 170234A
- Manufacturer: Trigen Laboratories, LLC
The hazard
The FDA said the 100-count product bottles labeled as Methylphenidate HCL ER Tablets 36 mg were found to contain 27 mg Methylphenidate HCL ER Tablets. This subpotency issue constitutes a Class III recall.
Context
GovInfoNow's records show Osmotica Pharmaceutical Corp has two other recalls on record since Sept. 16, 2013. A Dec. 18, 2017, recall involved Methylphenidate Tablets for subpotent drug risk. Other recent recalls of similar products include Unichem busPIRone 5mg Tablets (April 13, 2026), IntegraDose Vasopressin (May 18, 2026), and Avantor Magnesium Chloride API (March 31, 2026).